SynthesisPharmacoEconomics2011
Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.
Synthesis in PharmacoEconomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic Evaluations.PharmacoEconomics - open · 2025Pooled it
- Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Economic evaluation of psychological treatments for common mental disorders in low- and middle-income countries: a systematic review.Health policy and planning · 2023Pooled it
- Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.Advances in therapy · 2022Pooled it
- Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.PharmacoEconomics · 2021Pooled it
- A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Pooled it
- Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.PharmacoEconomics · 2013Pooled it
- Trial
- Affecting patients with work-related problems by educational training of their GPs: a cost-effectiveness study.BMC family practice · 2019Trial
- Economic Evaluation of an Internet-Based Preventive Cognitive Therapy With Minimal Therapist Support for Recurrent Depression: Randomized Controlled Trial.Journal of medical Internet research · 2018Trial
- Cost-utility analysis of a collaborative care intervention for major depressive disorder in an occupational healthcare setting.Journal of occupational rehabilitation · 2014Trial
- The hidden costs of Dutch dietary choices: quantifying the health and environmental costs attributable to suboptimal diets.Frontiers in nutrition · 2026Article
- [Disease, social, and economic burden of smoking in Brazil and the impact of tax increases on the economy and on the reduction of morbidity and mortality].Cadernos de saude publica · 2026Article
- Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- A novel set of Austrian reference unit costs for comprehensive societal perspectives consistent with latest European costing methods for economic evaluations.Wiener klinische Wochenschrift · 2024Article
- Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs.PharmacoEconomics · 2023Article
- Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects.PharmacoEconomics · 2023Article
- Out-of-pocket Expenses and Time Spent on Clinic Visits Among HIV Pre-exposure Prophylaxis Users and Other Clinic Attendees in Eswatini.AIDS and behavior · 2023Observational
- The association between health costs and physical inactivity; analysis from the Physical Activity at Work study in Thailand.Frontiers in public health · 2023Article
- A systemmatic literature review on indirect costs of women with breast cancer.Cost effectiveness and resource allocation : C/E · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhen guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the results of cost-effectiveness studies, particularly those regarding treatments targeted at diseases with a high incidence rate in the working population, such as depressive disorders.
objectivesThis study aimed to, first, investigate whether economic evaluations of treatments for depressive disorders include productivity costs and, if so, how. Second, to investigate how the inclusion or exclusion of productivity costs affects incremental costs.
methodsA systematic literature review was performed. Included articles were reviewed to determine (i) whether productivity costs had been included and (ii) whether the studies adhered to national health economic guidelines about the inclusion or exclusion of these costs. For those studies that did include productivity costs, we calculated what proportion of total costs were productivity costs. Subsequently, the incremental costs, excluding productivity costs, were calculated and compared with the incremental costs presented in the original article, to analyse the impact of productivity costs on final results. Regression analyses were used to investigate the relationship between the level of productivity costs and the type of depressive disorder, the type of treatment and study characteristics such as time horizon used and productivity cost valuation method.
resultsA total of 81 unique economic evaluations of treatments for adults with depressive disorders were identified, 24 of which included productivity costs in the numerator and one in the denominator. Approximately 69% of the economic evaluations ignored productivity costs. Two-thirds of the studies complied with national guidelines regarding the inclusion of productivity costs. For the studies that included productivity costs, these costs reflected an average of 60% of total costs per treatment arm. The inclusion or exclusion of productivity costs substantially affected incremental costs in a number of studies. Regression analyses showed that the level of productivity costs was significantly associated with study characteristics such as average age, the methods of data collection regarding work time lost, the values attached to lost work time, the type of depressive disorder, the type of treatment provided and the level of direct costs.
conclusionsStudies that do not include productivity costs may, in many cases, poorly reflect full societal costs (or savings) of an intervention. Furthermore, when comparing total costs reported in studies that include productivity costs, it should be noted that study characteristics such as the methods used to assess productivity costs may affect their level.
Indexed as
Identifiers
21545189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.